Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells
Despite efficacy <i>in vitro</i>, treatments failed to reduce xenograft tumor volumes. Hence, we conclude that this treatment strategy lacks direct cancer cell-intrinsic cytotoxic efficacy <i>in vivo</i>.
Authors
- Jasmine M. Manouchehri
- Lynn M. Marcho
- Jharna Datta
- Christopher C. Coss (ORCID: https://orcid.org/0000-0002-8184-9190)
- Mathew Cherian (ORCID: https://orcid.org/0000-0002-0380-2012)
- Menglin Xu (ORCID: https://orcid.org/0000-0001-7895-0733)
Institutions
- The Ohio State University (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-03-26
- DOI
- https://doi.org/10.3389/fonc.2025.1441896
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52